A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma

(2009) M. Maurer et al.   CANCER RESEARCH

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization

(2008) Elizabeth Iorns et al.   BIOCHEMICAL JOURNAL

Small-Molecule Inhibitors of PDK1

(2008) Christian Peifer et al.   ChemMedChem

The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors

(2008) Craig Lindsley et al.   CURRENT CANCER DRUG TARGETS

mTOR inhibitors in the treatment of cancer

(2008) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mutation of the PDK1 PH Domain Inhibits Protein Kinase B/Akt, Leading to Small Size and Insulin Resistance

(2008) J. R. Bayascas et al.   MOLECULAR AND CELLULAR BIOLOGY

The PTEN–PI3K pathway: of feedbacks and cross-talks

(2008) A Carracedo et al.   ONCOGENE